<DOC>
	<DOCNO>NCT01794143</DOCNO>
	<brief_summary>The GRADE Study pragmatic , unmasked clinical trial compare commonly use diabetes medication , combine metformin , glycemia-lowering effectiveness patient-centered outcome .</brief_summary>
	<brief_title>A Comparative Effectiveness Study Major Glycemia-lowering Medications Treatment Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Glimepiride</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<mesh_term>Dipeptidyl-Peptidase IV Inhibitors</mesh_term>
	<criteria>1 . Men woman diagnose diabetes age ≥ 30 year ( ≥ 20 American Indians ) 2 . Duration diagnose diabetes &lt; 10 year 3 . HbA1c criterion ( final runin visit , ~2 week prior randomization ) : 6.88.5 % 4 . Taking daily dose ≥ 1000 mg metformin minimum 8 week final runin 5 . Willingness administer daily subcutaneous injection , take second diabetes drug randomization , potentially initiate insulin intensify insulin therapy study metabolic goal meet , perform selfmonitoring blood glucose 6 . Fluent either English Spanish 7 . A negative pregnancy test female childbearing potential ( i.e . premenopausal , surgically sterile ) 8 . Provision sign date informed consent prior study procedure 1 . Suspected type 1 diabetes ( lean polyuria , polydipsia , weight loss little response metformin ) `` secondary '' diabetes due specific cause ( e.g . previously diagnose monogenic syndrome , pancreatic surgery , pancreatitis ) 2 . Current previous ( within past 6 month ) treatment diabetes drug/glucoselowering medication metformin ( limited use longer seven day allow , example hospitalization ) 3 . More 10 year treatment metformin time randomization screen 4 . History intolerance allergy contraindication propose study medication 5 . Resides household another GRADE study participant 6 . Current need specific glucoselowering medication solely condition , example polycystic ovary syndrome 7 . Symptomatic hyperglycemia require immediate therapy screen runin , judgment physician 8 . A lifethreatening event within 30 day prior screen currently plan major surgery 9 . Any major cardiovascular event previous year , include history myocardial infarction , stroke , vascular procedure coronary artery peripheral bypass grafting , stent placement ( peripheral coronary ) angioplasty . 10 . Plans pregnancy course study woman childbearing potential 11 . History plan bariatric surgery , include banding procedure surgical gastric and/or intestinal bypass ( band remove , may consider eligible 1 year ) 12 . History congestive heart failure ( NYHA 3 great ) 13 . History pancreatitis 14 . History cancer , nonmelanoma skin cancer , require therapy 5 year prior randomization 15 . Personal family history MEN2 family history medullary thyroid cancer 16 . Estimated GFR ( eGFR ) &lt; 30 ml/min/1.73 m2 end stage renal disease require renal replacement therapy 17 . History severe liver disease acute hepatitis ALT &gt; 3 time upper limit normal 18 . Current alcoholism excessive alcohol intake 19 . Previous organ transplant 20 . Treatment oral systemic glucocorticoid ( shortterm treatment , example poison ivy ) disease likely require periodic regular glucocorticoid therapy ( inhaled steroid allow ) 21 . Treatment atypical antipsychotic 22 . History hemolytic anemia , chronic transfusion requirement , condition render HbA1c result unreliable indicator chronic glucose level , hematocrit &lt; 35 male &lt; 33 female 23 . Clinically medically unstable expect survival &lt; 1 year 24 . Unwillingness permit site contact PCP communicate information study participant 's data 25 . No nonstudy PCP inability identify PCP ( provide nonstudy care ) time final runin 26 . Participation another interventional clinical trial 27 . Previous randomization GRADE study 28 . In opinion principal investigator ( PI ) , factor , include language barrier , likely limit compliance protocol</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Treatment Type 2 diabetes</keyword>
	<keyword>Comparative effectiveness research</keyword>
	<keyword>Clinical trial</keyword>
	<keyword>Patient-centered outcome</keyword>
</DOC>